Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

A doctor takes on Big Pharma

In “Sickening,” Harvard professor John Abramson chronicles the deceptive marketing practices of the drug industry

Salon

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Two years into the pandemic, unequal access to COVID-19 treatments threatens the global recovery

It’s now two years since the World Health Organization began calling the COVID-19 outbreak a pandemic.

The Conversation

Fears over drug used to treat Covid and link to serious birth defects

One expert says similar drugs have been shown to cause animals to be born with no teeth or parts of skull missing

Wales Online

Molnupiravir: why are there potential safety issues around this COVID antiviral?

If you’re worried about COVID, there’s a simple way to boost protection: get vaccinated. But this doesn’t work for everyone. People with weak immune systems – perhaps because of age or a medical condition – don’t respond well to vaccines. For them, COVID still poses a significant risk.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Why Alpine Immune's Shares Are Falling Today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and…

Benzinga

WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients

A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended molnupiravir for patients with non-severe disease at high risk of hospitalization, such as the immunocompromised, the unvaccinated, older people, and those with chronic conditions. The recommendation was…

Benzinga

WHO Recommends Merck COVID Pill for non-severe, at-risk patients

The World Health Organization on Wednesday recommended an anti-Covid pill be taken by sufferers who have mild symptoms but are at high risk of hospitalization, such as older people or the unvaccinated. The pill, called molnupiravir and developed by US pharmaceutical Merck, is taken as soon as possible after Covid-19…

Asharq Al-Awsat

EXPLAINER: Why Pfizer needs time to make COVID-19 treatment

Pfizer’s new COVID-19 treatment came with a catch when it debuted late last year: It can take months to make the tablets

The Independent UK

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies.

Benzinga

Hundreds queue in the snow as 50 jobs go up for grabs at science and technology firm

On the first day, 355 candidates queued around the Riverside hotel in the snow.

Daily Record

3 Wide-Moat Stocks to Withstand a Market Downturn: Microsoft, Merck, and Blackbaud

The major stock market indices suffered a sell-off as the news of Russia’s military action in Ukraine broke. But because wide-moat companies generally fare well in challenging times like these, we believe VanEck Vectors Morningstar Wide Moat ETF’s (MOAT) holdings Microsoft (MSFT), Merck & Co. (MRK), and Blackbaud (BLKB) might…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization

The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill mo

Benzinga

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE: MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country.

Benzinga

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.

Daily Record

More than 50 jobs up for grabs in Irvine as Merck announce recruitment event

Attendees will have the chance to meet with site staff and recruiters to talk about the many positions available.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Merck & Co Inc's (NYSE: MRK) Q4 sales re

Benzinga

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was

Benzinga

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,

The Guardian - UK

Testing for fully vaccinated travellers to UK to be scrapped; new vaccine pass rules in France – as it happened

UK transport secretary says testing rules for travellers into country will change from 4am on 11 February; new France rules come into force

Benzinga

Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report

Bloomberg reported that Merck & Co Inc (NYSE: MRK) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya' ransomware' attacks.

Benzinga

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

Key Takeaways

1 … 10 11 12 13

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

915 stories

WTO

504 stories

Food and Drug Administration

Regeneron Pharmaceuticals Inc

45 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.